Delving into the Latest Updates on NATCO Group, Inc. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Digestive System Disorders

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Bcr-Abl(Bcr-Abl tyrosine kinase)	1

Bexarotene is a retinoid X receptor agonist originally approved for anti-cancer activity, which was found to have anti-psoriatic activity in recent studies.However, its poor water solubility and high log P makes it difficult to deliver via topical route.Incorporation of bexarotene into liposome will address this issue by improving the solubility and permeability of the drug.In this study, bexarotene liposomes were prepared by optimization of different parameters including lipid to cholesterol ratio, sonication time, percent drug loading and entrapment efficiency.Optimized liposomes of particle size and size distribution (67.8.2 ± 7.15 nm, 0.26 ± 0.02 PDI) with greater than 90% entrapment efficiency were incorporated into gel and tested for rheol. behavior and drug release.Dermal uptake studies of dye loaded liposomes showed improved penetration compared to plain dye.Pharmacodynamic studies performed by employing imiquimod induced psoriatic plaque model in BALB/c mice confirmed effective reversal of psoriasis from liposomal bexarotene as indicated by reduced scaling, inflammation without any toxicity.Further histopathol. and cytokine level changes also confirmed the recovery of animals treated with liposomal gel formulation.These results concluded that, formulating bexarotene into liposomal gel improved anti-psoriatic efficacy of the drug.

01 Jan 2020·Smart Nanocontainers

Nanoscale characterization of nanocarriers

Author: Wahid Khan ; Ranga Goud Rayapolu ; Shaheen Mahira

Abstract Nanotechnology is increasingly receiving attention, as the small size of nanocarriers show enhanced properties like high reactivity, strength, surface area, stability, etc. Nanoscale level characterization of nanocarriers presents unique physical, chemical, and biological properties compared to their respective particles at higher scales. To elucidate their physicochemical properties, understanding the nanocarrier structure is important, which greatly influences their behavior in the body at molecular and systemic levels. USFDA has set, or is currently developing, some standard characterization methods for nanomaterials (ISO 22412, ASTME 2859-11). Moreover, to expedite the transition of benchtop efforts to clinically effective products, it is necessary to employ adequate methods to characterize nanocarriers, to correlate their effects and biological consequences, and to predict the therapeutic outcomes in clinical subjects at an early stage of product development. This chapter focuses on various critical quality attributes, methods, and sophisticated instruments available for nanoparticulate characterization for researchers to explore the nanoworld.

02 Dec 2014·ChemInform

ChemInform Abstract: Design and Optimization of Ecofriendly One‐Pot Synthesis of 2,4,5‐Triaryl‐1H‐imidazoles by Three‐Component Condensation Using Response Surface Methodology.

Author: C. V. S. Subrahmanyam ; T. Durai Ananda Kumar ; K. Satyanarayana ; N. Yamini

AbstractAn extensive statistical method is used to optimize the reaction parameters (e.g. catalyst and catalyst concentration, solvent and solvent volume) for the synthesis of 2,4,5‐triaryl‐1H‐imidazoles (III).

100 Deals associated with NATCO Group, Inc.

Login to view more data

100 Translational Medicine associated with NATCO Group, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Login to view more data